The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Mostrar otras versiones (1)

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Sglt-2 Inhibition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275453/
https://www.ncbi.nlm.nih.gov/pubmed/30524708
http://dx.doi.org/10.1093/ckj/sfy090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275453/
https://www.ncbi.nlm.nih.gov/pubmed/30524708
http://dx.doi.org/10.1093/ckj/sfy090

Ejemplares similares